IMMPImmutep Limited
The Read
1% on the Phase II breast cancer data update despite securities fraud lawsuits, while also rising 7.
The schedule
- Thu15Oct
High risk of dilutive equity financing to replenish the balance sheet for upcoming regulatory interactions. A measured raise could stabilize the stock at $0.15, but highly dilutive terms would likely flush shares to $0.06.
- Sun28Feb
FDA end-of-Phase II feedback which will dictate the size, cost, and design of pivotal Phase III studies. Clarity and alignment target $0.15, while requests for additional pre-pivotal data trigger $0.02.
- Wed3Mar
- Wed31Mar
Deadline for Nasdaq minimum bid compliance, likely necessitating a reverse stock split. A successful strategic pivot or clean consolidation could prompt a relief rally to $0.06, but mechanical selling risks $0.01.
- Wed2Jun
- Wed1Sep
Q4 2026 financial update focusing on late-stage pipeline progress and updated 2027 capital requirements. In-line execution supports $0.12, whereas delayed strategic timelines risk a dip to $0.04.
Past
- Fri18Sep
Actual outcome: Bear · $3.67 at outcome
IMMP experienced a significant short-term decline due to disappointing clinical trial results, which raised concerns about the drug's efficacy and regulatory approval timeline. The move suggests the data may have fallen short of expectations, potentially impacting the company's path to market and investor sentiment. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: -25.5% from 2026-09-18 to 2026-10-05 (~2.1σ vs typical 10d vol). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-05). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-06: -29.0% from 2026-09-21 (~2.4σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-06). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-07: -29.0% from 2026-09-21 (~2.4σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-07). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-08: -25.9% from 2026-09-22 (~2.1σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-08). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-09: -28.5% from 2026-09-25 (~2.3σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-09). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-12: -28.5% from 2026-09-25 (~2.4σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-12).
IMMP experienced a significant short-term decline due to disappointing clinical trial results, which raised concerns about the drug's efficacy and regulatory approval timeline. The move suggests the data may have fallen short of expectations, potentially impacting the company's path to market and investor sentiment. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: -25.5% from 2026-09-18 to 2026-10-05 (~2.1σ vs typical 10d vol). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-05). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-06: -29.0% from 2026-09-21 (~2.4σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-06). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-07: -29.0% from 2026-09-21 (~2.4σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-07). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-08: -25.9% from 2026-09-22 (~2.1σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-08). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-09: -28.5% from 2026-09-25 (~2.3σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-09). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-12: -28.5% from 2026-09-25 (~2.4σ). Target evaluation date 2026-10-13 (not yet reached as of 2026-10-12).
- Wed2Sep
Q1 2026 earnings print serving as a critical update on operating cash flow and pipeline advancement. The market will look for reassurance against cash runway concerns, targeting $0.25 on disciplined spend, or $0.10 on worsening burn.
- Mon15Jun
Actual outcome: Bull · $0.41 at outcome
Immutep was hit with a wave of securities fraud class action lawsuits around the event date. Despite this influx of negative legal news, the stock rallied 10.1% by the outcome date, indicating that the market largely looked past the litigation and kept shares well above the $0.15 bear floor.
Crucial clinical readout for eftilagimod alpha in metastatic breast cancer. Success could re-rate the stock to $0.70, while mixed or poor efficacy profiles threaten a drop to $0.15.
- Thu4Jun
Actual outcome: Bull · $0.42 at outcome
Stock rose 7.8% from event to outcome date, aligning with the bull trajectory.
An interim update from Immutep’s eftilagimod alpha combination trial in non-small cell lung cancer expected around late November 2026 will be another major proof-of-concept moment. From a depressed $0.18 base, encouraging response and durability data could re-rate the stock toward $0.60, while an unconvincing signal or safety flags would drive it closer to $0.10.